Aetiology of fulminant hepatitis

Viral Hepatitis

Volumn , Issue , 2007, Pages 649-665

  Promrat, Kittichai ^a   Wands, Jack R ^b  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

Acute liver failure (ALF); Hepatitis A virus (HAV); Hepatitis B virus (HBV) infection; Hepatitis C virus (HCV); Hepatitis delta virus (HDV)

Indexed keywords

EID: 84889811302     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987131.ch43     Document Type: Chapter

References (209)

1. Trey C, Davidson CS. The management of fulminant hepatic failure. In: Popper H, Schaffner F, eds. Progress in Liver Failure. New York: Grune & Stratton, 1970:282-98.
2. Hoofnagle JH, Carithers RL, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop. Hepatology 1995;21:240-52.
3. Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure; definition and causes. Semin Liver Dis 1986;6:97-106.
4. O’Grady JG, Schalm S, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993;342:373-5.
5. Lee WM. Acute liver failure in the United States. Semin Liver Dis 2003;23:217-26.
6. Ostapowicz G, Fontana RJ, Schiodt FV et al. U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-54.
7. Bernal W. Changing patterns of causation and the use of transplantation in the United Kingdom. Semin Liver Dis 2003;23:227-37.
8. Ritt DJ, Whelan G, Werner DJ, Eigenbrodt EH, Schenker S, Combes B. Acute hepatic necrosis with stupor or coma. An analysis of thirty-one patients. Medicine (Baltimore) 1969;48:151-72.
9. Acute Hepatic Failure Study Group. Rakela J, Mosley JW, Edwards VM, Govindarajan S, Alpert E. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. Dig Dis Sci 1991;36:1223-8.
10. Schiodt FV, Davern TJ, Shakil AO, McGuire B, Samuel G, Lee WM. Viral hepatitis-related acute liver failure. Am J Gastroenterol 2003;98:448-53.
11. Cheng VC, Lo CM, Lau GK. Current issues and treatment of fulminant hepatic failure including transplantation in Hong Kong and the Far East. Semin Liver Dis 2003;23:239-50.
12. Dhiman RK, Seth AK, Jain S, Chawla YK, Dilawari JB. Prognostic evaluation of early indicators in fulminant hepatic failure by multivariate analysis. Dig Dis Sci 1998;43:1311-16.
13. Acharya SK, Dasarathy S, Kumer TL et al. Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome. Hepatology 1996;23:1448-55.
14. Khuroo MS, Kamili S. Aetiology and prognostic factors in acute liver failure in India. J Viral Hepat 2003;10:224-31.
15. Schiodt FV, Atillasoy E, Shakil AO et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg 1999;5:29-34.
16. Shakil AO, Kramer D, Mazariegos GV, Fung JJ, Rakela J. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl 2000;6:163-9.
17. Centers for Disease Control and Prevention (CDC). Summary of notifiable diseases - United States, 2001. MMWR Morb Mortal Wkly Rep 2003;50:i-xxiv, 1-108.
18. Centers for Disease Control and Prevention (CDC). Hepatitis a outbreak associated with green onions at a restaurant - Monaca, Pennsylvania, 2003. MMWR Morb Mortal Wkly Rep 2003;52:1155-7.
19. O’Grady JG. Fulminant hepatitis in patients with chronic liver disease. J Viral Hepat 2000;7(Suppl. 1)):9-10.
20. Chadha MS, Walimbe AM, Chobe LP, Arankalle VA. Comparison of etiology of sporadic acute and fulminant viral hepatitis in hospitalized patients in Pune, India during 1978-81 and 1994-97. Indian J Gastroenterol 2003;22:11-15.
21. Centeno MA, Bes DF, Sasbon JS. Mortality risk factors of a pediatric population with fulminant hepatic failure undergoing orthotopic liver transplantation in a pediatric intensive care unit. Pediatr Crit Care Med 2002;3:227-33.
22. Uribe M, Buckel E, Ferrario M et al. Epidemiology and results of liver transplantation for acute liver failure in Chile. Transplant Proc 2003;35:2511-12.
23. Shah U, Habib Z, Kleinman RE. Liver failure attributable to hepatitis A virus infection in a developing country. Pediatrics 2000;105:436-8.
24. O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-45.
25. Kyrlagkitsis I, Cramp ME, Smith H, Portmann B, O’Grady J. Acute hepatitis A virus infection: a review of prognostic factors from 25 years experience in a tertiary referral center. Hepatogastroenterology 2002;49:524-8.
26. Vento S, Garofano T, Renzini C et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-90.
27. Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995;90:201-5.
28. Chu CM, Liaw YF. The incidence of fulminant hepatic failure in acute viral hepatitis in Taiwan: increased risk in patients with pre-existing HBsAg carrier state. Infection 1990;18:200-3.
29. Myers RP, Gregor JC, Marotta PJ. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C. Hepatology 2000;31:834-9.
30. Arguedas MR, Heudebert GR, Fallon MB, Stinnett AA. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States. Am J Gastroenterol 2002;97:721-8.
31. Rezende G, Roque-Afonso AM, Samuel D et al. Viral and clinical factors associated with the fulminant course of hepatitis A infection. Hepatology 2003;38:613-18.
32. Fujiwara K, Yokosuka O, Fukai K, Imazeki F, Saisho H, Omata M. Analysis of full-length hepatitis A virus genome in sera from patients with fulminant and self-limited acute type A hepatitis. J Hepatol 2001;35:112-19.
33. Fujiwara K, Yokosuka O, Ehata T et al. Association between severity of type A hepatitis and nucleotide variations in the 5' non-translated region of hepatitis A virus RNA: strains from fulminant hepatitis have fewer nucleotide substitutions. Gut 2002;51:82-8.
34. Fujiwara K, Yokosuka O, Imazeki F et al. Analysis of the genotype- determining region of hepatitis A viral RNA in relation to disease severities. Hepatol Res 2003;25:124-34.
35. Gane E, Sallie R, Saleh M, Portmann B, Williams R. Clinical recurrence of hepatitis A following liver transplantation for acute liver failure. J Med Virol 1995;45:35-9.
36. Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003;23:39-46.
37. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 199;336:1855-9.
38. Bianco E, Stroffolini T, Spada E et al. SEIEVA Collaborating Group. Case fatality rate of acute viral hepatitis in Italy: 1995-2000. An update. Dig Liver Dis 2003;35:404-8.
39. Rakela J, Lange SM, Ludwig J, Baldus WP. Fulminant hepatitis:Mayo Clinic experience with 34 cases. Mayo Clin Proc 1985;60:289-92.
40. Fan ST, Lo CM, Lo RJ et al. Management of fulminant hepatic failure at Queen Mary Hospital. Chin Med J (Engl) 1997;110:482-4.
41. Chu CM, Liaw YF. The incidence of fulminant hepatic failure in acute viral hepatitis in Taiwan: increased risk in patients with pre-existing HBsAg carrier state. Infection 1990;18:200-3.
42. Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001;139:349-52.
43. Saracco G, Macagno S, Rosina F, Rizzetto M. Serologic markers with fulminant hepatitis in persons positive for hepatitis B surface antigen. A worldwide epidemiologic and clinical survey. Ann Intern Med 1988;108:380-3.
44. Mels GC, Bellati G, Leandro G et al. Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations. Liver 1994;14:175-81.
45. Wright TL, Mamish D, Combs C et al. Hepatitis B virus and apparent fulminant non-A, non-B hepatitis. Lancet 1992;339:952-5.
46. Inokuchi K, Nakata K, Hamasaki K et al. Prevalence of hepatitis B or C virus infection in patients with fulminant viral hepatitis. An analysis using polymerase chain reaction. J Hepatol 1996;24:258-64.
47. Fukai K, Yokosuka O, Fujiwara K et al. Etiologic considerations of fulminant non-A, non-B viral hepatitis in Japan: analyses by nucleic acid amplification method. J Infect Dis 1998;178:325-33.
48. Sallie R, Rayner A, Naoumov N, Portmann B, Williams R. Occult HBV in NANB fulminant hepatitis. Lancet 1993;341:123.
49. Feray C, Gigou M, Samuel D et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology 1993;104:549-55.
50. Fagan EA, Harrison TJ. Exclusion in liver by polymerase chain reaction of hepatitis B and C viruses in acute liver failure attributed to sporadic non-A, non-B hepatitis. J Hepatol 1994;21:587-91.
51. Laskus T, Rakela J, Wiesner RH, Steers JL, Persing DH. Lack of evidence for hepatitis B virus (HBV) infection in fulminant non-A, non-B hepatitis. Dig Dis Sci 1994;39:1677-82.
52. Mutimer D, Shaw J, Neuberger J et al. Failure to incriminate hepatitis B, hepatitis C, and hepatitis E viruses in the aetiology of fulminant non-A non-B hepatitis. Gut 1995;36:433-6.
53. Hytiroglou P, Dash S, Haruna Y et al. Detection of hepatitis B and hepatitis C viral sequences in fulminant hepatic failure of unknown etiology. Am J Clin Pathol 1995;104:588-93.
54. Mason A, Sallie R, Perrillo R et al. Prevalence of herpesviridae and hepatitis B virus DNA in the liver of patients with non-A, non-B fulminant hepatic failure. Hepatology 1996;24:1361-5.
55. Teo EK, Ostapowicz G, Hussain M, Lee WM, Fontana RJ, Lok AS; US ALF Study Group (Acute Liver Failure). Hepatitis B infection in patients with acute liver failure in the United States. Hepatology 2001;33:972-6.
56. Perrillo RP, Campbell CR, Sanders GE, Regenstein FG, Bodicky CJ. Spontaneous clearance and reactivation of hepatitis B virus infection among male homosexuals with chronic type B hepatitis. Ann Intern Med 1984;100:43-6.
57. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975;2:528-30.
58. Thung SN, Gerber MA, Klion F, Gilbert H. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med 1985;145:1313-14.
59. Bird GL, Smith H, Portmann B, Alexander GJ, Williams R. Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers. Q J Med 1989;73:895-902.
60. Lau JY, Lai CL, Lin HJ et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 1989;73:911-17.
61. Pinto PC, Hu E, Bernstein-Singer M, Pinter-Brown L, Govindarajan S. Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 1990;65:878-84.
62. Webster A, Brenner MK, Prentice HG, Griffiths PD. Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant 1989;4:207-8.
63. Pariente EA, Goudeau A, Dubois F et al. Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogeneic bone marrow transplantation. Dig Dis Sci 1988;33:1185-91.
64. Caselitz M, Link H, Hein R et al. Hepatitis B associated liver failure following bone marrow transplantation. J Hepatol 1997;27:572-7.
65. Lau GK, Leung YH, Fong DY et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002;99:2324-30.
66. Lau GK, He ML, Fong DY et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36:702-9.
67. Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002;36:1246-52.
68. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001;115:58-62.
69. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressiveinduced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002;100:391-6.
70. Fagan EA, Smith PM, Davison F, Williams R. Fulminant hepatitis B in successive female sexual partners of two anti-HBepositive males. Lancet 1986;2:538-40.
71. Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991;324:1705-9.
72. Terazawa S, Kojima M, Yamanaka T et al. Hepatitis B virus mutants with precore-region defects in two babies with fulminant hepatitis and their mothers positive for antibody to hepatitis B e antigen. Pediatr Res 1991;29:5-9.
73. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 1991;324:1699-704.
74. Hasegawa K, Huang JK, Wands JR, Obata H, Liang TJ. Association of hepatitis B viral precore mutations with fulminant hepatitis B in Japan. Virology 1991;185:460-3.
75. Kosaka Y, Takase K, Kojima M et al. Fulminant hepatitis B: induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. Gastroenterology 1991;100:1087-94.
76. Carman WF, Fagan EA, Hadziyannis S et al. Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology 1991;14:219-22.
77. Li JS, Tong SP, Wen YM, Vitvitski L, Zhang Q, Trepo C. Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant:possible contribution of a single nucleotide in the precore region. J Virol 1993;67:5402-10.
78. Feray C, Gigou M, Samuel D, Bernuau J, Bismuth H, Bréchot C. Low prevalence of precore mutations in hepatitis B virus DNA in fulminant hepatitis type B in France. J Hepatol 1993;18:119-22.
79. Laskus T, Persing DH, Nowicki MJ, Mosley JW, Rakela J. Nucleotide sequence analysis of the precore region in patients with fulminant hepatitis B in the United States. Gastroenterology 1993;105:1173-8.
80. Liang TJ, Hasegawa K, Munoz SJ et al. Hepatitis B virus precore mutation and fulminant hepatitis in the United States. A polymerase chain reaction-based assay for the detection of specific mutation. J Clin Invest 1994;93:550-5.
81. Ogata N, Miller RH, Ishak KG, Purcell RH. The complete nucleotide sequence of a pre-core mutant of hepatitis B virus implicated in fulminant hepatitis and its biological characterization in chimpanzees. Virology 1993;194:263-76.
82. Sato S, Suzuki K, Akahane Y et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995;122:241-8.
83. Chu CJ, Keeffe EB, Han SH et al. U.S. HBV Epidemiology Study Group. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003;38:619-28.
84. Friedt M, Gerner P, Lausch E, Trubel H, Zabel B, Wirth S. Mutations in the basic core promotor and the precore region of hepatitis B virus and their selection in children with fulminant and chronic hepatitis B. Hepatology 1999;29:1252-8.
85. Laskus T, Rakela J, Nowicki MJ, Persing DH. Hepatitis B virus core promoter sequence analysis in fulminant and chronic hepatitis B. Gastroenterology 1995;109:1618-23.
86. Hasegawa K, Huang J, Rogers SA, Blum HE, Liang TJ. Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. J Virol 1994;68:1651-9.
87. Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest 1996;98:2268-76.
88. Baumert TF, Marrone A, Vergalla J, Liang TJ. Naturally occurring mutations define a novel function of the hepatitis B virus core promoter in core protein expression. J Virol 1998;72:6785-95.
89. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996;70:5845-51.
90. Parekh S, Zoulim F, Ahn SH et al. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol 2003;77:6601-12.
91. Sterneck M, Kalinina T, Gunther S et al. Functional analysis of HBV genomes from patients with fulminant hepatitis. Hepatology 1998;28:1390-7.
92. Stuyver L, De Gendt S, Cadranel JF et al. Three cases of severe subfulminant hepatitis in heart-transplanted patients after nosocomial transmission of a mutant hepatitis B virus. Hepatology 1999;29:1876-83.
93. Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 2003;38:1075-86.
94. Leifeld L, Cheng S, Ramakers J et al. Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis B. Hepatology 2002;36(4 Pt 1)):1001-8.
95. Naoumov NV, Schneider R, Grotzinger T et al. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology 1992;102:538-43.
96. Pollicino T, Zanetti AR, Cacciola I et al. Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis. Hepatology 1997;26:495-9.
97. Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 1995;345:1406-7.
98. Kalinina T, Riu A, Fischer L, Will H, Sterneck M. A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis. Hepatology 2001;34:385-94.
99. Imamura T, Yokosuka O, Kurihara T et al. Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan. Gut 2003;52:1630-7.
100. Wai CT, Fontana RJ, Schilsky M et al and the U.S. Acute Liver Failure Study Group. Molecular epidemiology of hepatitis B virus related acute liver failure in the United States: a multicenter case control study. Hepatology 2003;38(Suppl.1)):815A
101. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002;36(5 Suppl. 1)):S93-S98.
102. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36(5 Suppl. 1)):S21-S29.
103. Wright TL, Hsu H, Donegan E et al. Hepatitis C virus not found in fulminant non-A, non-B hepatitis. Ann Intern Med 1991;115:111-12.
104. Theilmann L, Solbach C, Toex U et al. Role of hepatitis C virus infection in German patients with fulminant and subacute hepatic failure. Eur J Clin Invest 1992;22:569-71.
105. Liang TJ, Jeffers L, Reddy RK et al. Fulminant or subfulminant non-A, non-B viral hepatitis: the role of hepatitis C and E viruses. Gastroenterology 1993;104:556-62.
106. Kuwada SK, Patel VM, Hollinger FB et al. Non-A, non-B fulminant hepatitis is also non-E and non-C. Am J Gastroenterol 1994;89:57-61.
107. Sallie R, Silva AE, Purdy M et al. Hepatitis C and E in non-A non-B fulminant hepatic failure: a polymerase chain reaction and serological study. J Hepatol 1994;20:580-8.
108. Villamil FG, Hu KQ, Yu CH et al. Detection of hepatitis C virus with RNA polymerase chain reaction in fulminant hepatic failure. Hepatology 1995;22:1379-86.
109. Yanagi M, Kaneko S, Unoura M et al. Hepatitis C virus in fulminant hepatic failure. N Engl J Med 1991;324:1895-6.
110. Yoshiba M, Sekiyama K, Sugata F, Okamoto H. Diagnosis of type C fulminant hepatitis by the detection of antibodies to the putative core proteins of hepatitis C virus. Gastroenterol Jpn 1991;26:234.
111. Chu CM, Sheen IS, Liaw YF. The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B. Gastroenterology 1994;107:189-95.
112. Vento S, Cainelli F, Mirandola F et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996;347:92-3.
113. Farci P, Alter HJ, Shimoda A et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med 1996;335:631-4.
114. Farci P, Shimoda A, Coiana A et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000;288:339-44.
115. Farci P, Munoz SJ, Shimoda A et al. Experimental transmission of hepatitis C virus-associated fulminant hepatitis to a chimpanzee. J Infect Dis 1999;179:1007-11.
116. Casey JL, Brown TL, Colan EJ, Wignall FS, Gerin JL. A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci USA 1993;90:9016-20.
117. Casey JL, Niro GA, Engle RE et al. Hepatitis B virus (HBV)/ hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F. J Infect Dis 1996;174:920-6.
118. Nakano T, Shapiro CN, Hadler SC et al. Characterization of hepatitis D virus genotype III among Yucpa Indians in Venezuela. J Gen Virol. 2001;82(Pt 9):2183-9.
119. Buitrago B, Hadler SC, Popper H et al. Epidemiologic aspects of Santa Marta hepatitis over a 40-year period. Hepatology 1986;6:1292-6.
120. Bensabath G, Hadler SC, Soares MC et al. Hepatitis delta virus infection and Labrea hepatitis. Prevalence and role in fulminant hepatitis in the Amazon Basin. JAMA 1987;258:479-83.
121. Manock SR, Kelley PM, Hyams KC et al. An outbreak of fulminant hepatitis delta in the Waorani, an indigenous people of the Amazon basin of Ecuador. Am J Trop Med Hyg 2000;63:209-13.
122. Flodgren E, Bengtsson S, Knutsson M et al. Recent high incidence of fulminant hepatitis in Samara, Russia: molecular analysis of prevailing hepatitis B and D virus strains. J Clin Microbiol 2000;38:3311-16.
123. Gaeta GB, Stroffolini T, Chiaramonte M et al. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology 2000;32(4 Pt 1)):824-7.
124. Rosina F, Conoscitore P, Cuppone R et al. Changing pattern of chronic hepatitis D in southern Europe. Gastroenterology 1999;117:161-6.
125. Lettau LA, McCarthy JG, Smith MH et al. Outbreak of severe hepatitis due to delta and hepatitis B viruses in parenteral drug abusers and their contacts. N Engl J Med 1987;317:1256-62.
126. Farci P, Smedile A, Lavarini C et al. Delta hepatitis in inapparent carriers of hepatitis B surface antigen. A disease simulating acute hepatitis B progressive to chronicity. Gastroenterology 1983;85:669-73.
127. Popper H, Thung SN, Gerber MA et al. Histologic studies of severe delta agent infection in Venezuelan Indians. Hepatology 1983;3:906-12.
128. Buitrago B, Popper H, Hadler SC et al. Specific histologic features of Santa Marta hepatitis: a severe form of hepatitis delta-virus infection in northern South America. Hepatology 1986;6:1285-91.
129. Lefkowitch JH, Goldstein H, Yatto R, Gerber MA. Cytopathic liver injury in acute delta virus hepatitis. Gastroenterology 1987;92(5 Pt 1)):1262-6.
130. Sanyal MC. Epidemic of infectious hepatitis amongst personnel of the armed forces, Delhi (1955-56): epidemiology. Indian J Med Res 1957;45(Suppl.)):91-9.
131. Arora NK, Nanda SK, Gulati S et al. Acute viral hepatitis types E, A, and B singly and in combination in acute liver failure in children in north India. J Med Virol 1996;48:215-21.
132. Hussaini SH, Skidmore SJ, Richardson P, Sherratt LM, Cooper BT, O’Grady JG. Severe hepatitis E infection during pregnancy. J Viral Hepat 1997;4:51-4.
133. Khuroo MS, Kamili S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. J Viral Hepat 2003;10:61-9.
134. Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI. Incidence and severity of viral hepatitis in pregnancy. Am J Med 1981;70:252-5.
135. Kane MA, Bradley DW, Shrestha SM et al. Epidemic non-A, non-B hepatitis in Nepal. Recovery of a possible etiologic agent and transmission studies in marmosets. JAMA 1984;252:3140-5.
136. Myint H, Soe MM, Khin T, Myint TM, Tin KM. A clinical and epidemiological study of an epidemic of non-A non-B hepatitis in Rangoon. Am J Trop Med Hyg 1985;34:1183-9.
137. Tsega E, Hansson BG, Krawczynski K, Nordenfelt E. Acute sporadic viral hepatitis in Ethiopia: causes, risk factors, and effects on pregnancy. Clin Infect Dis 1992;14:961-5.
138. Yoshiba M, Okamoto H, Mishiro S. Detection of the GBV-C hepatitis virus genome in serum from patients with fulminant hepatitis of unknown aetiology. Lancet 1995;346:1131-2.
139. Yoshiba M, Inoue K, Sekiyama K. Hepatitis GB virus C. N Engl J Med 1996;335:1392-3.
140. Heringlake S, Osterkamp S, Trautwein C et al. Association between fulminant hepatic failure and a strain of GBV virus C. Lancet 1996;348:1626-9.
141. Inoue K, Yoshiba M, Sekiyama K, Kohara M. Possible association between serum GB virus C RNA level and disease activity in fulminant hepatitis type G. J Hepatol 1999;30:801-6.
142. Wu JC, Chiang TY, Huang YH et al. Prevalence, implication, and viral nucleotide sequence analysis of GB virus-C/hepatitis G virus infection in acute fulminant and nonfulminant hepatitis. J Med Virol 1998;56:118-22.
143. Haydon GH, Jarvis LM, Simpson KJ, Hayes PC, Simmonds P. The clinical significance of the detection of hepatitis GBV-C RNA in the serum of patients with fulminant, presumed viral, hepatitis. J Viral Hepat 1997;4:45-9.
144. Kanda T, Yokosuka O, Ehata T et al. Detection of GBV-C RNA in patients with non-A-E fulminant hepatitis by reverse-transcription polymerase chain reaction. Hepatology 1997;25:1261-5.
145. Halasz R, Barkholt L, Lara C et al. Relation between GB virus C/hepatitis G virus and fulminant hepatic failure may be secondary to treatment with contaminated blood and/or blood products. Gut 1999;44:274-8.
146. Munoz SJ, Alter HJ, Nakatsuji Y et al. The significance of hepatitis G virus in serum of patients with sporadic fulminant and subfulminant hepatitis of unknown etiology. Blood 1999;94:1460-4.
147. Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun 1997;241:92-7.
148. Charlton M, Adjei P, Poterucha J et al. TT-virus infection in North American blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis. Hepatology 1998;28:839-42.
149. Matsumoto A, Yeo AE, Shih JW, Tanaka E, Kiyosawa K, Alter HJ. Transfusion-associated TT virus infection and its relationship to liver disease. Hepatology 1999;30:283-8.
150. Gimenez-Barcons M, Forns X, Ampurdanes S et al. Infection with a novel human DNA virus (TTV) has no pathogenic significance in patients with liver diseases. J Hepatol 1999;30:1028-34.
151. Kao JH, Chen W, Hsiang SC, Chen PJ, Lai MY, Chen DS. Prevalence and implication of TT virus infection: minimal role in patients with non-A-E hepatitis in Taiwan. J Med Virol 1999;59:307-12.
152. Tanaka M, Nishiguchi S, Tanaka T et al. Prevalence of TT virus in patients with fulminant hepatic failure in Japan. J Gastroenterol 1999;34:589-93.
153. Umemura T, Yeo AE, Sottini A et al. SEN virus infection and its relationship to transfusion-associated hepatitis. Hepatology 2001;33:1303-11.
154. Umemura T, Tanaka E, Ostapowicz G et al. Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis. J Infect Dis 2003;188:1545-52.
155. Kaufman B, Gandhi SA, Louie E, Rizzi R, Illei P. Herpes simplex virus hepatitis: case report and review. Clin Infect Dis 1997;24:334-8.
156. Farr RW, Short S, Weissman D. Fulminant hepatitis during herpes simplex virus infection in apparently immunocompetent adults: report of two cases and review of the literature. Clin Infect Dis 1997;24:1191-4.
157. Chase RA, Pottage JC Jr, Haber MH, Kistler G, Jensen D, Levin S. Herpes simplex viral hepatitis in adults: two case reports and review of the literature. Rev Infect Dis 1987;9:329-33.
158. Anuras S, Summers R. Fulminant herpes simplex hepatitis in an adult: report of a case in renal transplant recipient. Gastroenterology 1976;70:425-8.
159. Johnson JR, Egaas S, Gleaves CA, Hackman R, Bowden RA. Hepatitis due to herpes simplex virus in marrow-transplant recipients. Clin Infect Dis 1992;14:38-45.
160. Marrie TJ, McDonald AT, Conen PE, Boudreau SF. Herpes simplex- hepatitus use of immunoperoxidase to demonstrate the viral antigen in hepatocytes. Gastroenterology 1982;82:71-6.
161. Klein NA, Mabie WC, Shaver DC et al. Herpes simplex virus hepatitis in pregnancy. Two patients successfully treated with acyclovir. Gastroenterology 1991;100:239-44.
162. Peters DJ, Greene WH, Ruggiero F, McGarrity TJ. Herpes simplex- induced fulminant hepatitis in adults: a call for empiric therapy. Dig Dis Sci 2000;45:2399-404.
163. Pinna AD, Rakela J, Demetris AJ, Fung JJ. Five cases of fulminant hepatitis due to herpes simplex virus in adults. Dig Dis Sci 2002;47:750-4.
164. Shanley CJ, Braun DK, Brown K et al. Fulminant hepatic failure secondary to herpes simplex virus hepatitis. Successful outcome after orthotopic liver transplantation. Transplantation 1995;59:145-9.
165. Paya CV, Hermans PE, Wiesner RH et al. Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations. J Infect Dis 1989;160:752-8.
166. Chan AY, Dieckhaus KD, Ramsey WH. Cytomegalovirus hepatitis in a nontransplant patient with autoimmune hepatitis taking immunosuppressants. Am J Gastroenterol 2001;96:262-3.
167. Kunno A, Abe M, Yamada M, Murakami K. Clinical and histological features of cytomegalovirus hepatitis in previously healthy adults. Liver 1997;17:129-32.
168. Miguelez M, Gonzalez A, Perez F. Severe cytomegalovirus hepatitis in a pregnant woman treated with ganciclovir. Scand J Infect Dis 1998;30:304-5.
169. Seehofer D, Rayes N, Tullius SG et al. CMV hepatitis after liver transplantation: incidence, clinical course, and long-term follow- up. Liver Transpl 2002;8:1138-46.
170. Colina F, Juca NT, Moreno E et al. Histological diagnosis of cytomegalovirus hepatitis in liver allografts. J Clin Pathol 1995;48:351-7.
171. Ishikawa K, Hasegawa K, Naritomi T et al. Prevalence of herpesviridae and hepatitis virus sequences in the livers of patients with fulminant hepatitis of unknown etiology in Japan. J Gastroenterol 2002;37:523-30.
172. Mason WR Jr, Adams EK. Infectious mononucleosis; an analysis of 100 cases with particular attention to diagnosis, liver function tests and treatment of selected cases with prednisone. Am J Med Sci 1958;236:447-59.
173. Feranchak AP, Tyson RW, Narkewicz MR, Karrer FM, Sokol RJ. Fulminant Epstein-Barr viral hepatitis: orthotopic liver transplantation and review of the literature. Liver Transpl Surg 1998;4:469-76.
174. Markin RS, Linder J, Zuerlein K et al. Hepatitis in fatal infectious mononucleosis. Gastroenterology 1987;93:1210-17.
175. Papatheodoridis GV, Delladetsima JK, Kavallierou L, Kapranos N, Tassopoulos NC. Fulminant hepatitis due to Epstein-Barr virus infection. J Hepatol 1995;23:348-50.
176. Langnas AN, Markin RS, Inagaki M et al. Epstein-Barr virus hepatitis after liver transplantation. Am J Gastroenterol 1994;89:1066-70.
177. Pitel PA, McCormick KL, Fitzgerald E, Orson JM. Subclinical hepatic changes in varicella infection. Pediatrics 1980;65:631-3.
178. Morishita K, Kodo H, Asano S, Fujii H, Miwa S. Fulminant varicella hepatitis following bone marrow transplantation. JAMA 1985;253:511.
179. Bensousan TA, Moal MC, Vincent F, Nousbaum JB, Bourbigot B. Fulminant hepatitis revealing primary varicella in a renal graft recipient. Transplant Proc 1995;27:2512.
180. Patti ME, Selvaggi KJ, Kroboth FJ. Varicella hepatitis in the immunocompromised adult: a case report and review of the literature. Am J Med 1990;88:77-80.
181. Anderson DR, Schwartz J, Hunter NJ, Cottrill C, Bisaccia E, Klainer AS. Varicella hepatitis: a fatal case in a previously healthy, immunocompetent adult. Report of a case, autopsy, and review of the literature. Arch Intern Med 1994;154:2101-6.
182. Morales JM. Successful acyclovir therapy of severe varicella hepatitis in an adult renal transplant recipient. Am J Med 1991;90:401.
183. Ross JS, Fanning WL, Beautyman W, Craighead JE. Fatal massive hepatic necrosis from varicella-zoster hepatitis. Am J Gastroenterol 1980;74:423-7.
184. Karetnyi YV, Beck PR, Markin RS, Langnas AN, Naides SJ. Human parvovirus B19 infection in acute fulminant liver failure. Arch Virol 1999;144:1713-24.
185. Sokal EM, Melchior M, Cornu C et al. Acute parvovirus B19 infection associated with fulminant hepatitis of favourable prognosis in young children. Lancet 1998;352:1739-41.
186. Langnas AN, Markin RS, Cattral MS, Naides SJ. Parvovirus B19 as a possible causative agent of fulminant liver failure and associated aplastic anemia. Hepatology 1995;22:1661-5.
187. Pardi DS, Romero Y, Mertz LE, Douglas DD. Hepatitis-associated aplastic anemia and acute parvovirus B19 infection: a report of two cases and a review of the literature. Am J Gastroenterol 1998;93:468-70.
188. Cattral MS, Langnas AN, Markin RS et al. Aplastic anemia after liver transplantation for fulminant liver failure. Hepatology 1994;20(4 Pt 1)):813-18.
189. Tung J, Hadzic N, Layton M et al. Bone marrow failure in children with acute liver failure. J Pediatr Gastroenterol Nutr 2000;31:557-61.
190. Wong S, Young NS, Brown KE. Prevalence of parvovirus B19 in liver tissue: no association with fulminant hepatitis or hepatitis- associated aplastic anemia. J Infect Dis 2003;187:1581-6.
191. Bertheau P, Parquet N, Ferchal F, Gluckman E, Brocheriou C. Fulminant adenovirus hepatitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996;17:295-8.
192. Cames B, Rahier J, Burtomboy G et al. Acute adenovirus hepatitis in liver transplant recipients. J Pediatr 1992;120:33-7.
193. Chakrabarti S, Collingham KE, Fegan CD, Milligan DW. Fulminant adenovirus hepatitis following unrelated bone marrow transplantation: failure of intravenous ribavirin therapy. Bone Marrow Transplant 1999;23:1209-11.
194. Wang WH, Wang HL. Fulminant adenovirus hepatitis following bone marrow transplantation. A case report and brief review of the literature. Arch Pathol Lab Med 2003;127:246-8.
195. Wang SM, Liu CC, Yang YJ, Yang HB, Lin CH, Wang JR. Fatal coxsackievirus B infection in early infancy characterized by fulminant hepatitis. J Infect 1998;37:270-3.
196. Huang QS, Carr JM, Nix WA et al. An echovirus type 33 winter outbreak in New Zealand. Clin Infect Dis 2003;37:650-7.
197. Read RB, Ede RJ, Morgan-Capner P, Moscoso G, Portmann B, Williams R. Myocarditis and fulminant hepatic failure from coxsackievirus B infection. Postgrad Med J 1985;61(718)):749-52.
198. Sobue R, Miyazaki H, Okamoto M et al. Fulminant hepatitis in primary human herpesvirus-6 infection. N Engl J Med 1991;324:1290.
199. Asano Y, Yoshikawa T, Suga S, Yazaki T, Kondo K, Yamanishi K. Fatal fulminant hepatitis in an infant with human herpesvirus-6 infection. Lancet 1990;335:862-3.
200. Harma M, Hockerstedt K, Lautenschlager I. Human herpesvirus-6 and acute liver failure. Transplantation 2003;76:536-9.
201. Fagan EA, Ellis DS, Tovey GM et al. Toga-like virus as a cause of fulminant hepatitis attributed to sporadic non-A, non-B. J Med Virol 1989;28:150-5.
202. Fagan EA, Ellis DS, Tovey GM et al. Toga virus-like particles in acute liver failure attributed to sporadic non-A, non-B hepatitis and recurrence after liver transplantation. J Med Virol 1992;38:71-7.
203. Phillips MJ, Blendis LM, Poucell S et al. Syncytial giant-cell hepatitis. Sporadic hepatitis with distinctive pathological features, a severe clinical course, and paramyxoviral features. N Engl J Med 1991;324:455-60.
204. Durand F, Degott C, Sauvanet A et al. Subfulminant syncytial giant cell hepatitis: recurrence after liver transplantation treated with ribavirin. J Hepatol 1997;26:722-6.
205. Hicks J, Barrish J, Zhu SH. Neonatal syncytial giant cell hepatitis with paramyxoviral-like inclusions. Ultrastruct Pathol 2001;25:65-71.
206. Lum LC, Lam SK, George R, Devi S. Fulminant hepatitis in dengue infection. Southeast Asian J Trop Med Public Health 1993;24:467-71.
207. de Filippis AM, Nogueira RM, Schatzmayr HG et al. Outbreak of jaundice and hemorrhagic fever in the Southeast of Brazil in 2001: detection and molecular characterization of yellow fever virus. J Med Virol 2002;68:620-7.
208. Acharya SK, Panda SK, Saxena A, Gupta SD. Acute hepatic failure in India: a perspective from the East. J Gastroenterol Hepatol 2000;15:473-9.
209. Takahashi Y, Shimizu M. Aetiology and prognosis of fulminant viral hepatitis in Japan: a multicentre study. The Study Group of Fulminant Hepatitis. J Gastroenterol Hepatol 1991;6:159-64.